MEDIUMBuilt-inProduct / Revenue mix
49%
HA products
“10-K Item 1A: 'Our HA products accounted for 49%, 46% and 43% of our total revenue for the years ended December 31, 2025, 2024 and 2023, respectively.'”
BVS · Concentration risk · 10-K extracted
Bioventus (BVS) concentration risks
Updated
The most significant concentration Bioventus discloses is HA products at 49%, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Bioventus’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH0
MEDIUM2
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partySupplier
third-party manufacturers
“10-K Item 1A: 'We rely on a limited number of third-party manufacturers to manufacture certain of our products and critical components.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Bioventus' concentration risk spans both product mix and manufacturing. Hyaluronic acid (HA) products accounted for 49%, 46%, and 43% of total revenue over the three most recent years, a medium-share, structural exposure reflecting the company's core product focus rather than dependence on a single counterparty — notably, this share has been rising year over year. On the supply side, Bioventus relies on a limited number of third-party manufacturers to produce certain products and critical components, a medium-share dependency exposure that could affect production continuity if one of those manufacturers were disrupted. The two exposures interact: because HA products represent a growing share of revenue, any manufacturing disruption affecting HA-related components would carry more weight than it would have in earlier years. Netting these together, Bioventus' risk is a combination of a structural, product-mix concentration in HA and a dependency-type exposure to a limited manufacturing base — neither alone is severe by the filing's own bands, but together they point to HA-product and manufacturing continuity as the areas most likely to move results if disrupted.
For the engine’s reasoning on BVS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| AVNS | Avanos Medical, Inc. | 2 | 0 | 1 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| BVS● | Bioventus Inc. | 0 | 2 | 0 | 2 |
| AHCO | AdaptHealth Corp. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.